Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive metastatic colorectal cancer (mCRC). Materials and Methods An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and irinotecan (120 mg/m2 days 1 and 8 every 3 weeks). The primary endpoint was the objective response rate. Results Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven patients (33.3%) achieved an objective res-ponse, and 11 patients (52.4%) had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% confidence interval, 2.7 to 5.9). Four of the 21 patients (19.0%) had grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the mitogen-activated protein kinase pathway, HER2 gene, phosphoinositide 3-kinase/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC. Conclusion Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number.
Abstract
Purpose The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive metastatic colorectal cancer (mCRC). Materials and Methods An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and irinotecan (120 mg/m2 days 1 and 8 every 3 weeks). The primary endpoint was the objective response rate. Results Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven patients (33.3%) achieved an objective res-ponse, and 11 patients (52.4%) had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% confidence interval, 2.7 to 5.9). Four of the 21 patients (19.0%) had grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the mitogen-activated protein kinase pathway, HER2 gene, phosphoinositide 3-kinase/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC. Conclusion Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number.
참고문헌 (29)
- Siena S, "Targeting the human epidermal growth factor receptor 2(HER2)oncogene in colorectal cancer", Ann Oncol, 29, pp.1108~1119 (2018)
- Whenham N, "HER2-positive breast cancer : from trastuzumab to innovatory anti-HER2 strategies", Clin Breast Cancer, 8, pp.38~49 (2008)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Kreutzfeldt J, "The trastuzumab era : current and upcoming targeted HER2+ breast cancer therapies", Am J Cancer Res, 10, pp.1045~1067 (2020)
- Oh DY, "HER2-targeted therapies-a role beyond breast cancer", Nat Rev Clin Oncol, 17, pp.33~48 (2020)
- Conradi LC, "Frequency of HER-2 positivity in rectal cancer and prognosis", Am J Surg Pathol, 37, pp.522~531 (2013)
- Wei Q, "Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA", Clin Colorectal Cancer, 18, pp.175~182 (2019)
- Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
- Valtorta E, "Assessment of a HER2 scoring system for colorectal cancer : results from a validation study", Mod Pathol, 28, pp.1481~1491 (2015)
- Martin V, "HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients", Br J Cancer, 108, pp.668~675 (2013)
- Bregni G, "HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer", JAMA Oncol, 5, pp.605~606 (2019)
- Clark JW, "Phase-II trial of 5-fluororuacil(5-FU), leucovorin(LV), oxaliplatin(Ox), and trastuzamab(T)for patients with metastatic colorectal cancer(CRC)refractory to initial therapy", Onkologie, 26(Suppl 3), pp.13~46 (2003)
- Ramanathan RK, "Low overexpression of HER-2", neu in advanced colorectal cancer limits the usefulness of trastuzumab(Herceptin)and irinotecan as therapy : a phase II trial, 2004, pp.22, 858~865
- Greulich H, "Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2", Proc Natl Acad Sci U S A, 109, pp.14476~14481 (2012)
- Nagano M, "High-throughput functional evaluation of variants of unknown significance in ERBB2", Clin Cancer Res, 24, pp.5112~5122 (2018)
- Mitra D, "An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance", Mol Cancer Ther, 8, pp.2152~2162 (2009)
- Castagnoli L, "Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab", Cancer Res, 74, pp.6248~6259 (2014)
- Peeters M, "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI)compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer", J Clin Oncol, 28, pp.4706~4713 (2010)
- Xu RH, "Modified XELIRI(capecitabine plus irinotecan)versus FOLFIRI(leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer(AXEPT) : a multicentre, open-label, randomised, non-inferiority, phase 3 trial", Lancet Oncol, 19, pp.660~671 (2018)
- Grothey A, "Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.303~312 (2013)
- Li J, "Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer : the FRESCO randomized clinical trial", JAMA, 319, pp.2486~2496 (2018)
- Meric-Bernstam F, "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway) : an updated report from a multicentre, open-label, phase 2a, multiple basket study", Lancet Oncol, 20, pp.518~530 (2019)
- Sartore-Bianchi A, "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12", 13 wild-type, HER2-positive metastatic colorectal cancer(HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial, 2016, pp.17, 738~746
- Pietrantonio F, "HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy : implication for further clinical research", Int J Cancer, 139, pp.2859~2864 (2016)
- Hainsworth JD, "Targeted therapy for advanced solid tumors on the basis of molecular profiles : results from MyPathway, an open-label, phase IIa multiple basket study", J Clin Oncol, 36, pp.536~542 (2018)
- Siravegna G, "Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer", Cancer Cell, 34, pp.148~162 (2018)
- Chandarlapaty S, "Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer", Clin Cancer Res, 18, pp.6784~6791 (2012)
- Wang DS, "Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer", Gut, 68, pp.1152~1161 (2019)
- Scaltriti M, "Cyclin E amplification", overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients, 2011, pp.108, 3761~3766